MA
ADPT icon

MYDA Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

MYDA Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,000
Closed -$309K – 108
2019
Q3 		$309K Buy
+10,000
New +$408K 0.14% 79

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

MYDA Advisors's ADPT Position: Q1 2020 in Review

MYDA Advisors sold out of Adaptive Biotechnologies (ADPT) in Q1 2020, closing a stake of 39,000 shares — an estimated $1.17M sold.

MYDA Advisors first reported a position in ADPT in Q2 2019 and held it in 3 quarters. The position peaked at $1.17M in Q4 2019. 147 funds tracked by Wall St. Rank hold ADPT as of Q1 2020.

  • MYDA Advisors reported no remaining Adaptive Biotechnologies position as of Q1 2020 after selling out during the quarter.
  • MYDA Advisors sold 39,000 Adaptive Biotechnologies shares in Q1 2020, an estimated $1.17M.
  • MYDA Advisors first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 3 quarters.
  • MYDA Advisors's Adaptive Biotechnologies position peaked at $1.17M in Q4 2019.
  • 147 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2020.

Based on MYDA Advisors's 13F filing for Q1 2020, filed 14 May 2020.